LMB In The News

RSS feed of lmb-in-the-news posts

Venki Ramakrishnan at World Economic Forum in Davos


The end of the antibiotic age? The LMB’s Venki Ramakrishnan took part in a panel discussion on the problem of antibiotic resistance at the World Economic Forum in Davos. In an interview with Katia Moskvitch, he tells us about the importance of gaining a better understanding of the use and misuse of these drugs. More…


Who made these covers and what are they doing here?


A cover image designed by Stephen Wallace from Jason Chin’s group at the LMB and Paul Margiotta from the LMB’s visual aids department is included in the Royal Society of Chemistry blog on cover art and the people who make it. More…


‘Hairclip’ protein mechanism explained

University Of Cambridge

A new study, involving LMB researchers and former LMB group leader, Sarah Teichmann, describes a fundamental mechanism regulating a protein’s shape and function, with potential applications in biotechnology and drug development. More…


Sjors Scheres named by Nature as one of ten people who mattered in 2014


LMB group leader Sjors Scheres is profiled by Nature as one of its ten people of the year, for his work on bringing the cell’s molecular machines into sharper focus, with the use of cryo-EM. More…


Heptares Therapeutics granted key patents for GPCR-Focused Drug Discovery Platform

MRC Technology

Heptares Therapeutics, a leading G protein-coupled receptor (GPCR) structure-guided drug discovery company, has recently been granted multiple key patents in the USA. GPCRs are a superfamily of drug receptors linked to a wide range of human diseases and Heptares was founded in 2007 to develop and commercialise pioneering research from the LMB and the National Institute of Medical Research (NIMR) to find new medicines targeting GPCRs. Sir John Saville presented the inventors with a memento to mark the award of these key patents for the GPCR-focused drug discovery platform. More…


LMB’s Pat Edwards interviewed for the Long and Short magazine


Pat Edwards discusses her role in Research Support at the LMB and why the LMB is such a special place to work. More…


Synthetic enzymes hint at life without DNA or RNA

New Scientist

Enzymes that don’t exist in nature have been made from genetic material that doesn’t exist in nature either, called XNA, or xeno nucleic acid. New Scientist reports how the breakthrough from Philipp Holliger’s group at the LMB reinforces the possibility that life could evolve without DNA or RNA, the two self-replicating molecules considered indispensible for life on Earth. More…


Major synthetic life breakthrough as LMB scientists make the first artificial enzymes

The Independent

For the first time ever, researchers have made synthetic enzymes – the vital ingredients needed for life – from artificial genetic material that does not exist outside the laboratory. This milestone from Philipp Holliger’s group at the LMB could soon lead to new ways of developing drugs and medical treatments, as reported in the Independent.


SELPEPCON – an exciting technology platform developed by the LMB’s Mike Gait


A technology platform to deliver cargoes using arrays of cell penetrating peptides was developed by the LMB’s Mike Gait, to help treat muscular degenerative diseases such as Duchenne muscular dystrophy. Further developments on this SELPEPCON technology, which was patented by the MRC and is licenced to Cambridge Research Biochemicals, are highlighted here.


Madan Babu to give Colworth Medal Lecture on 1st December


Madan, from the LMB’s Structural Studies Division, will present his award lecture and receive the prestigious 2014 Colworth Medal at the Biochemical Society’s AGM, on Monday 1st December at Charles Darwin House, London. Anyone wishing to attend should register in advance here.